Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood insulin amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,211 days,7,,CMO:0000358,serum insulin level,,,,0.000213,mg/dl,0.0,1.0E-4,MMO:0000113,oral glucose tolerance test,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",67476,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood free fatty acid amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000547,serum free fatty acids level,,,,0.75,mmol/l,0.052,0.1376,MMO:0000308,serum free fatty acid analysis,,0.0,"Wako Pure Chemicals, Tokyo, Japan",,,days,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67496,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",epididymal fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000658,epididymal fat pad weight to body weight ratio,,,,1.48,%,0.12,0.3175,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67492,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",retroperitoneal fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000635,retroperitoneal fat pad weight to body weight ratio,,,,1.48,%,0.13,0.3439,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67472,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",retroperitoneal fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000356,retroperitoneal fat pad weight,,,,5.5,g,0.5,1.3229,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12789,specific pathogen-free condition (for 210 days),fasting (for 1 days), 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000046,blood glucose level,,,,88.8,mg/dl,1.4,5.6,MMO:0000113,oral glucose tolerance test,tail,,"Arkray, Kyoto, Japan",gastric gavage,0,min,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",13211,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000046,blood glucose level,,,,127,mg/dl,3.2,12.8,MMO:0000113,oral glucose tolerance test,tail,,"Arkray, Kyoto, Japan",gastric gavage,30,min,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",13212,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000046,blood glucose level,,,,127.1,mg/dl,3.5,14.0,MMO:0000113,oral glucose tolerance test,tail,,"Arkray, Kyoto, Japan",gastric gavage,60,min,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",13213,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000046,blood glucose level,,,,126.8,mg/dl,2.7,10.8,MMO:0000113,oral glucose tolerance test,tail,,"Arkray, Kyoto, Japan",gastric gavage,90,min,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",13214,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000046,blood glucose level,,,,124.8,mg/dl,2.6,10.4,MMO:0000113,oral glucose tolerance test,tail,,"Arkray, Kyoto, Japan",gastric gavage,120,min,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",13215,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,211 days,7,,CMO:0000046,blood glucose level,,,,78.7,mg/dl,3.4,8.9956,MMO:0000113,oral glucose tolerance test,,0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",12786,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood triglyceride amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000360,serum triglyceride level,,,,89.9,mg/dl,6.73,17.8059,MMO:0000136,serum triglyceride analysis,,0,"Wako Pure Chemicals, Tokyo, Japan",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),13193,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",mesenteric fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000355,mesenteric fat pad weight,,,,4.4,g,0.7,1.852,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12788,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood cholesterol amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000363,serum total cholesterol level,,,,65.8,mg/dl,2.93,7.7521,MMO:0000132,serum total cholesterol measurement test,,0,"Wako Pure Chemicals, Tokyo, Japan",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12787,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",epididymal fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000357,epididymal fat pad weight,,,,5.5,g,0.5,1.3229,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12790,specific pathogen-free condition (for 210 days),fasting (for 1 days), 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",body mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000012,body weight,,,,366.8,g,4.2,16.8,MMO:0000016,body weighing method,,,,,,,fasting (for 16 hours),11985,fasting (for 16 hours),, 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",body mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,211 days,7,,CMO:0000012,body weight,,,,368.7,g,8.7,23.018,MMO:0000016,body weighing method,,,,oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",12791,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",mesenteric fat pad mass,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,218 days,7,,CMO:0000654,mesenteric fat pad weight to body weight ratio,,,,1.18,%,0.15,0.3969,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67468,specific pathogen-free condition (for 210 days),fasting (for 1 days), 230,"Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62.",blood glucose amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,210 days,16,,CMO:0000350,blood glucose level area under curve (AUC),,,,14626.9,(mg/dl) x min,209.1,836.4,MMO:0000113,oral glucose tolerance test,tail,0.0,"Arkray, Kyoto, Japan",gastric gavage,,,"fasting (for 16 hours) then glucose solution, 2.8M (2 g/kg) ",67779,fasting (for 16 hours),"glucose solution, 2.8M (2 g/kg) ", 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood adiponectin amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,211 days,7,,CMO:0000583,serum adiponectin level,,,,3.03,ng/ml,0.23,0.6085,MMO:0000075,enzyme linked immunosorbent assay,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67480,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood leptin amount,,RS:0001734,F344.OLETF-(D7Mgh16-D7Mgh20)/Tj,male,211 days,7,,CMO:0000780,serum leptin level,,,,2.8,ng/ml,0.54,1.4287,MMO:0000075,enzyme linked immunosorbent assay,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,7,days,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",67484,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) "